{
    "clinical_study": {
        "@rank": "94129", 
        "arm_group": {
            "arm_group_label": "MDCs transplant", 
            "arm_group_type": "Experimental", 
            "description": "The women who have stress urinary incontinency."
        }, 
        "brief_summary": {
            "textblock": "This study was designed to provide confirmation of safety of muscle derived cell (MDCs) for\n      the treatment of stress urine incontinency (SUI) in women."
        }, 
        "brief_title": "Autologous Muscle Derived Stem Cells Transplantation in Urine Incontinency", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Stress Incontinency", 
        "detailed_description": {
            "textblock": "The investigators will be assessed the 12-month safety and potential efficacy of autologous\n      muscle derived cells as therapy for stress urinary incontinence. A total of 10 women in whom\n      stress urinary incontinence had not improved underwent intra-sphincter injection of low\n      doses 30\u00d7106 of autologous muscle derived cells, which will be derived from biopsies of\n      their deltoid muscle. Assessments will be made at 1, 3, 6 and 12 months after cell\n      injection. Changes in stress urinary incontinence severity were evaluated by pad test, diary\n      of incontinence episodes and quality of life surveys."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female\n\n          -  Stress Urinary Incontinence symptoms\n\n          -  Urodynamic stress incontinence confirmed with multichannel urodynamic testing\n\n          -  positive cough stress test\n\n          -  urgency score < stress score\n\n          -  Patient's age between 40 - 65 years\n\n          -  Desire to surgical correction of stress urinary incontinence or inadequate response\n             to conservative treatment of SUI\n\n        Exclusion Criteria:\n\n          -  Post-void residual volume >100cc\n\n          -  Detrusor overactivity on preoperative multichannel urodynamic testing\n\n          -  History of previous synthetic, biologic or fascial sub-urethral sling or any other\n             surgery on external genitalia, bladder neck, bladder or urethra\n\n          -  Desires future childbearing\n\n          -  Chronic inguinal or vulvar abscess or history of Hidradenitis Suppurative\n\n          -  History of bleeding diathesis or current anti-coagulation therapy\n\n          -  Inguinal lymphadenopathy or inguinal/vulvar mass\n\n          -  Current genitourinary fistula or urethral diverticulum\n\n          -  Current sever cystocele or rectocele\n\n          -  Active urinary infection\n\n          -  Non-treated urge incontinency or any significant voiding dysfunction\n\n          -  Neuromuscular disorders\n\n          -  Uncontrolled Diabetes\n\n          -  Reversible cause of incontinence (i.e. drug effect)\n\n          -  Contraindications for surgery"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963455", 
            "org_study_id": "royan-Kidney-001"
        }, 
        "intervention": {
            "arm_group_label": "MDCs transplant", 
            "description": "MDCs transplantation by paraurethral injection .", 
            "intervention_name": "paraurethral injection of MDCs", 
            "intervention_type": "Biological", 
            "other_name": "MDCs transplantion by paraurethral injection."
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "transplantation autologous stress urinary incontinence", 
            "muscle derived cells"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "link": {
            "url": "http://royaninstitute.org"
        }, 
        "location": {
            "contact": {
                "email": "nasser.aghdami@royaninstitute.org", 
                "last_name": "Nasser Aghdami, MD,PhD", 
                "phone": "(+98)2123562000", 
                "phone_ext": "514"
            }, 
            "contact_backup": {
                "email": "Leara91@gmail.com", 
                "last_name": "Leila Arab, MD", 
                "phone": "(+98)2123562000", 
                "phone_ext": "414"
            }, 
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of"
                }, 
                "name": "Royan Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Mohammad Naji, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Maryam Taheri, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Effect Evaluation of Autologous Muscle Derived Stem Cells Injection Into the Paraurethral Tissues for Treatment of Urinary Incontinency", 
        "overall_contact": {
            "email": "nasser.aghdami@royaninstitute.org", 
            "last_name": "Nasser Aghdami, MD,PhD", 
            "phone": "(+98)2123562000", 
            "phone_ext": "514"
        }, 
        "overall_contact_backup": {
            "email": "Leara91@gmail.com", 
            "last_name": "Leila Arab, MD", 
            "phone": "(+98)2123562000", 
            "phone_ext": "414"
        }, 
        "overall_official": [
            {
                "affiliation": "Head of Royan Institute", 
                "last_name": "Hamid Gourabi, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Head of Department of Regenerative Medicine And Royan Cell Therapy Center Royan Institute For stem Cell Biology and Technology", 
                "last_name": "Nasser Aghdami, MD,PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Urology and Nephrology Research Center, Shahid Beheshti University", 
                "last_name": "Farzaneh Sharifiaghdas, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Department of Regenerative Medicine And Royan Cell Therapy Center Royan Institute For stem Cell Biology and Technology", 
                "last_name": "Reza Moghadasali, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran", 
                "last_name": "Farzam Tajali, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Iran: Ethics Committee", 
                "Iran: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation the 24hours voiding diary reduction by patient questionaire 2h pad test and By clinical measures by cystourethroscopy and urodynamic  before , 1, 3,6 and 12 months after MDCs injection.", 
            "measure": "24hours voiding diary reduction", 
            "safety_issue": "Yes", 
            "time_frame": "1month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963455"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluation the enhance incontinence quality of life (I-Qol) by questionnaire form, before injection of MDCs, 1, 3,6 and 12 months after injection.", 
            "measure": "Enhance incontinence quality of life (I-Qol)", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "source": "Royan Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Royan Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}